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httcense.Abstract Background and objective: Several studies have investigated the association of obstruc-
tive sleep apnea syndrome (OSAS) with depression and anxiety; however, the relationship is still
poorly understood. Therefore, we aimed to assess anxious and depressive symptoms in OSA, and
evaluate their association with potentially related variables of OSAS.
Subjects and methods: This study included 72 patients newly diagnosed with obstructive sleep
apnea and 30 controls. Patients underwent an overnight polysomnography and were assessed using
the Epworth sleepiness scale (ESS) for excessive daytime sleepiness (EDS), hospital anxiety and
depression scale (HAD) for anxious and depressive symptoms, and Maugeri obstructive sleep apnea
syndrome (MOSAS) questionnaire for quality of life (QOL).
Results: 72 OSA patients (60 men and 12 women) whose mean age was 48.8 ± 11.73 yr and
mean apnea and hypopnea index (AHI) was 64 ± 21.86, were compared with 30 controls according
to their HAD scores. We found that the HAD score for anxiety and depression was higher in OSA
patients than in the control group (p= 0.001 and 0.002 respectively). Moreover, the prevalence of
symptoms of anxiety in patients with OSA was 33% while that of depression was 51%. Linear
regression analysis revealed that daytime sleepiness and reduced QOL were strong predictors of
depressive symptoms in OSA patients (P= 0.001 and 0.002 respectively), while reduced QOL
was the only predictor of anxious symptoms (p= 0.035). No signiﬁcant relations were found
between severity of psychological symptoms and AHI or nocturnal hypoxemia in OSA patients.
Conclusion: Anxious and depressive symptoms are highly prevalent in patients with moderate to
severe untreated OSAS. The severity of depressive symptoms maybe more related to excessivepartment of Chest Diseases,
e, Alexandria, Egypt.
. Daabis).
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172 R. Daabis, H. Gharrafdaytime sleepiness than to nocturnal hypoxemia. The reduced QOL is a strong predictor of psychi-
atric symptoms in OSAS patients. Therefore, patients with OSAS should be routinely screened for
psychiatric symptoms to improve QOL and optimize diagnosis and therapy in these patients.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
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Obstructive sleep apnea (OSA) is by far the most common form
of sleep-disordered breathing,which is associatedwith increased
morbidity and mortality and diminished quality of life [1]. It is
characterized by recurrent episodes of upper airway obstruction
during sleep, which induces nocturnal hypoxemia, hypercapnia
and sleep fragmentation [2]. It subsequently results in excessive
daytime sleepiness, mood problems, poor neurocognitive per-
formance as well as serious organ system dysfunction [3]. Fati-
gue, daytime sleepiness, lack of energy, irritability, headache
and insomnia are common symptoms of OSAS, some of which
resembles symptoms associated with anxious and depressive
conditions.However, cliniciansmay have problems differentiat-
ing psychiatric disease from symptoms related to organic disease
[4]. Over the past few years, the burgeoning interest in psycho-
pathological changes in patients with sleep-disordered breath-
ing (SDB) has resulted in a large increase in the number of
published studies on this topic [5]. Several studies have investi-
gated the association of OSAS with depression and anxiety;
however, the relationship is still poorly understood [4,6–9]. In-
creased awareness of the relationship between these psychiatric
comorbidities andOSASmight signiﬁcantly improve diagnostic
accuracy as well as treatment outcome for both disorders [10].
The hospital anxiety and depression scale (HAD) is a well-doc-
umented instrument for assessing symptoms of anxiety and
depression in patients with somatic diseases [11]. Therefore,
we aimed to assess anxious and depressive symptoms as themost
prevalent psychological disturbances in OSAS using the HAD
scale, and evaluate their association with potentially related
variables in patients with newly diagnosed OSAS.
Subjects and methods
This study included 72 patients newly diagnosed with obstruc-
tive sleep apnea, as well as 30 controls who had no personal his-
tories of psychiatric diseases, snoring and/ or other sleep
disorders.
Patients’ exclusion criteria were; CPAP/BiPAP therapy, the
presence of other sleep disorders, presence of obstructive lung
disease, the presence of a signiﬁcant comorbidity such as
malignancy, severe heart failure or stroke, or refusal to ﬁll
out psychological questionnaires.
Data were collected regarding anthropometric measure-
ments, demographic factors, smoking, clinical parameters like
observed apnea by partner and co-morbid conditions as diabe-
tes or hypertension.
Nocturnal sleep studies
All patients underwent overnight polysomnography using
Respironics Alice 5 system (RESMED, Germany Inc). It is a
level I device that records parameters such as body position,effort (thorax and abdomen), nasal ﬂow (canula and/or therm-
istor), snoring (canula and/or microphone), SpO2, plethysmo-
gram, pulse rate, ECG, CPAP/BiPAP, and PLM overnight in
hospital. Recordings of at least 5 h were required to validate
the sleep study. The analysis was carried out automatically
and manually. Respiratory events were scored using standard
criteria [12,13]. The apnea hypopnea index (AHI) was deﬁned
as the total number of apneas and hypopneas per hour of
sleep. As indices of nocturnal hypoxemia we considered the
oxygen desaturation index (this is the number of times that
the oxygen saturation falls by more than 3 or 4 percent per
hour of sleep), T90 (the fraction of sleep time spent below an
oxygen saturation of 90 percent) and the minimal value re-
corded during sleep (minimal SaO2) [12,13].
The study inclusion criteria were an age of >18 years and a
conﬁrmed diagnosis of OSAS based on the AHI: AHIP 15
events per hour or AHIP 5 and 614 events per hour with
documented sleep symptoms or documented hypertension,
ischemic heart disease, or a history of stroke [13].
Assessment of daytime sleepiness
The Epworth sleepiness scale (ESS) was used for assessing day-
time sleepiness. This is a commonly used self-administered scale
with eight items about how easily the respondent would fall
asleep in different situations. The items are scored on a 0–3 scale,
which are added to give an overall score of 0–24. Higher scores
indicate more sleepiness. ESS score 2–10 is considered ‘normal’
and >10 indicative of pathological sleepiness [14].
Assessment of anxiety and depression
Symptoms of anxiety and depression were measured with the
hospital anxiety and depression scale (HADS). The HADS is
a validated and reliable psychological measure widely used in
both hospitalized and primary care patients with chronic dis-
eases. The HADS is divided into an anxiety subscale (HADS-
A) and a depression subscale (HADS-D) both containing seven
items, rated 0–3, giving a possible maximum score for anxiety
and depression of 21. The scores range from 0 to 21 for each sub-
scale, with a score of 0–7 denoting a noncase, 8–10 a possible
case, and 11 or higher a probable case [11].
Assessment of quality of life (QOL)
We used the new validated Maugeri obstructive sleep apnea
syndrome (MOSAS) questionnaire which is used to assess
the psychological and physical impact of OSAS as well as
the adherence to the CPAP device. Its items cover the domains
of normal daily routine, social interactions emotional func-
tioning, and symptoms. It is composed of 2 sections; section
A consists of 16 items, scored on a 1–4 scale, divided into
two factors: sleep apnea Psychological Impact (10 items) and
Table 2 Comparison of the HAD anxiety and depression
scales in the patients and control group.
OSA patients Control P
HADS-A 11.1 ± 3.09 4.25 ± 2.63 0.001*
HADS-D 14.8 ± 4.11 6.5 ± 2.65 0.002*
p:p value for Student t-test.
HADS-A: hospital anxiety and depression subscale for anxiety.
HADS-D: hospital and depression subscale for depression.
* Statistically signiﬁcant at p 6 0.05.
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Figure 1 Comparison of the HAD anxiety and Depression scales
in the patients and control group. HAD-A: hospital anxiety and
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appropriate ﬁller items., and section B measures the discom-
fort and nuisance caused by CPAP use (7 items) and therefore
was not applied in our patients. Higher score means greater
psychological or physical impact [15].
All subjects were enrolled in the study after a written in-
formed consent according to the protocol approved by the
Ethics Committee of the Hospital.
Statistical analysis
Data were collected, tabulated, then analyzed using SPSS Ver-
sion13. Qualitative data were presented as numbers and per-
centage. Quantitative data were expressed as means and
standard deviation. Groups were compared for demographic
and clinical characteristics and scores on the questionnaire
measures using unpaired t-test. Pearson correlation coefﬁcient
(r) was used to assess the relation between HAD anxiety and
depression scores and numeric variables. Linear regression
analysis was used to examine the inﬂuence of confounding fac-
tors affecting depression and anxiety scores. For all statistical
tests, a p-value of 60.05 was considered signiﬁcant.
Results
72 newly diagnosed OSAS patients were enrolled in this study;
they were 60 men and 12 women and their mean age wasTable 1 Patients Characteristics.
Gender, n (%)
Male 60 (83)
Female 12 (17)
Age 48.8 ± 11.73
BMI 42.8 ± 6.51
Smoking status, n (%)
Current smoker 25 (35)
Ex-smoker 12 (17)
Never smoker 35 (49)
ESS 17.8 ± 4.07
Observed apnea by partner, n (%) 54 (75)
Comorbities, n (%)
HTN 36 (50)
DM 18 (25)
Others 15 (21)
AHI 64 ± 21.86
ODI 50.4 ± 18.71
T90 48.8 ± 18.76
Minimum SaO2 65.2 ± 11.02
MOSAS-A 42.1 ± 6.11
Results are expressed as mean + standard deviation unless other-
wise speciﬁed. Deﬁnition of abbreviations: n: number of patients,
BMI:body mass index, ESS:Epworth sleepiness scale, HTN:hyper-
tension, DM:diabetes mellitus, AHI: apnea hypopnea index,
ODI:oxygen desturation index, T90: fraction of sleep time spent
below an oxygen saturation of 90 percent, SaO2: arterial oxygen
saturation, MOSAS:Maugeri obstructive sleep apnea syndrome
questionnaire.
depression scale for anxiety HAD-D: Hospital and depression
scale for depression.48.8 ± 11.73 yr. Their mean AHI was 64 ± 21.86 indicating
that they were on average suffering from severe obstructive
sleep apnea. The patients’ characteristics are shown in Table 1.
HAD scores of the patient group were compared with a con-
trol group including 30 healthy adults (24 men and 8 women,
mean age 50.0 ± 1.22 yr) randomly selected and age- and sex-
matched (Table 2 and Fig. 1).
Twenty-four patients (33%) had an anxiety score ofP11
(probable anxiety), and 37 patients (51%) had a depression
score ofP11 (probable depression). The characteristics of pa-
tients with and without anxiety and/or depression are shown
in Tables 3 and 4.
Depressed patients had more daytime sleepiness, measured
by the Epworth sleepiness scale, as compared with non-
depressed patients, However, depressed patients showed no
signiﬁcant differences as regards sex, age, BMI, smoking,
comorbidities, respiratory sleep parameters and QOL.
In addition, anxious patients showed no signiﬁcant differ-
ence from non-anxious patients regarding the different demo-
graphic, clinical and respiratory sleep parameters as well as
QOL (Tables 3 and 4).
Correlation analysis of the HAD anxiety and depression scores
with other parameters
Correlation analyses of the HAD scores and numeric
parameters (demographic, clinical, respiratory sleep parame-
ters, and QOL) showed that the HAD depression score was
signiﬁcantly correlated with daytime sleepiness and reduced
QOL (p= 0.002 for both), while the HAD anxiety score was
signiﬁcantly correlated with QOL only (p= 0.035). Moreover,
Table 3 Descriptive statistics according to HAD anxiety score.
Anxious Not anxious P value
Score < 11 ScoreP 11
N= 24 N= 48
Gender, n(%)
Male 21 (88) 39 (81) NS
Female 3 (13) 9 (19)
Age 45.3 ± 9.25 50.5 ± 13.01 NS
BMI 42.5 ± 6.66 42.9 ± 6.9 NS
Smoking status, n (%)
Current smoker 7 (29) 18 (38) NS
Ex-smoker 9 (38) 3 (6)
Never smoker 8 (33) 27 (56)
ESS 19.8 ± 2.63 16.8 ± 4.43 NS
Observed apnea by partner, number (%) 20 (83) 34 (71) NS
Comorbities (n)
HTN 12 (50) 24 (50) NS
DM 4 (21) 13 (27)
Others 6 (25) 9 (19)
AHI 67.8 ± 18.41 64.0 ± 24.51 NS
ODI 58.3 ± 16.90 48.8 ± 19.83 NS
T90 51.8 ± 13.07 47.9 ± 21.88 NS
Minimum SO2 71.3 ± 2.50 64.3 ± 16.11
MOSAS-A 45.3 ± 1.89 40.5 ± 6.97 NS
HADS-D 16.5 ± 4.04 14.0 ± 4.4 NS
Results are expressed as mean + standard deviation unless otherwise speciﬁed. p:p value for Student t-test, n: number of patients, BMI:body
mass index, ESS:Epworth sleepiness scale, HTN:hypertension, DM:diabetes mellitus, AHI:apnea hypopnea index, ODI:oxygen desturation
index, T90: fraction of sleep time spent below an oxygen saturation of 90 percent, SaO2: arterial oxygen saturation.
MOSAS:Maugeri obstructive sleep apnea syndrome questionnaire, HADS-D: Hospital and depression scale for depression.
174 R. Daabis, H. Gharrafthere was a signiﬁcant positive correlation between the HAD
anxiety and depression scores (see Table 5).
Linear regression analysis was done to control for potentially
confounding factors affecting the depression and anxiety scores.
A regression analysis model was done for each score separately
with the HAD score as the dependant variable and with all the
demographic, clinical, respiratory sleep parameters well as QOL
measured by the MOSAS questionnaire as the independent vari-
ables. Reduced QOL, measured by the MOSAS questionnaire,
was a signiﬁcant predictor of both anxiety and depression. In
addition, daytime sleepiness measured by the ESS was addi-
tional signiﬁcant predictor of depression only Table 6.Discussion
In this study, we aimed to determine the prevalence of anxious
and depressive symptoms in treatment-naı¨ve moderate to se-
vere OSA patients, and their relation with different variables
of obstructive sleep apnea syndrome. During the study period,
the majority of patients referred for assessment for possible
OSA were male patients (60 males and 12 females), this dis-
crepancy might reﬂect the increased incidence of OSA in males
reported in several studies [2], but could also be due to bias in
referral with more male patients referred for the sleep study.
We found that the prevalence of symptoms of anxiety in
patients with OSA was 33% while that of depression was51%. Moreover, the HAD score for anxiety and depression
was higher in OSA patients than in the control group
(p= 0.001 and 0.002 respectively). This high prevalence is in
line with ﬁndings reported in some studies in which OSA
was highly associated with anxiety and/or depression
[2,4,8,9]. Prevalence ﬁgures for depression and anxiety varied
widely, even between studies using the same method of assess-
ment, showing a marked variety in the prevalence of both
depression (7–63%) and anxiety (11–70%) [16].
Several studies have investigated the association of OSAS
with depression and anxiety; however, the relationship is still
poorly understood. In untreated OSAS, rates of depression
are elevated compared with general populations [8,9], although
not necessarily at a pathological level [7]. In contrast, some
other studies have been unable to conﬁrm this association be-
tween OSAS and anxiety or depression [4]. Some of the mixed
ﬁndings among studies can be explained by differences in sam-
ple size, study population, gender distribution, age, variability
in scales used to assess anxiety and depression and the overlap
between mood alteration and OSAS-related symptoms [3,10].
This high prevalence of depressive symptoms in OSA pa-
tients can be explained by several possible underlying mecha-
nisms. The two main factors suspected to be responsible for
depressive symptoms in OSAS are sleep fragmentation and
oxygen desaturation during sleep. Sleep fragmentation is a di-
rect consequence of the recurrent microarousals associated
with the apneas and hypopneas, and the nocturnal hypoxemia
Table 4 Descriptive statistics according to HAD depression score.
Depressed Not depressed P value
Score < 11 ScoreP 11
N= 37 N= 35
Gender (n)
Male 30 (81) 30 (86) NS
Female 7 (19) 5 (14)
Age 45.3 ± 9.25 50.5 ± 13.01 0.06
BMI 44.2 ± 4.45 41.3 ± 8.29 NS
Smoking status, n(%)
Current smoker 18 (49) 7 (20) NS
Ex-smoker 7 (19) 5 (14)
Never smoker 12 (32) 23 (66)
ESS 20.3 ± 1.97 15.2 ± 4.07 0.019*
Observed apnea by partner, number (%) 30 (81) 24 (68) NS
Comorbities (n)
HTN 20 (54) 16 (46) NS
DM 10 (27) 8 (23) NS
Others 7 (19) 8 (23)
AHI 72.2 ± 13.01 58.3 ± 19,9 NS
ODI 56.5 ± 13.72 47.3 ± 20.14 NS
T90 54.8 ± 20.64 46.5 ± 14.74 NS
Minimum SO2 62.2 ± 12.34 67.3 ± 8.7 NS
MOSAS-A 45.17 ± 2.99 39 ± 7.10 0.078
HADS-A 12.17 ± 2.04 10.0 ± 3.74 NS
Results are expressed as mean + standard deviation unless otherwise speciﬁed. p:p value for Student t-test, n: number of patients, BMI:body
mass index, ESS:Epworth sleepiness scale, HTN:hypertension, DM:diabetes mellitus, AHI:apnea hypopnea index, ODI:oxygen desturation
index, T90: fraction of sleep time spent below an oxygen saturation of 90 percent, SaO2: arterial oxygen saturation, MOSAS:Maugeri
obstructive sleep apnea syndrome questionnaire, HADS-A: Hospital and depression scale for anxiety.
* Statistically signiﬁcant at p 6 0.05.
Table 5 Correlation of the HAD anxiety and depression
scores with the Epworth sleepiness scale (ESS) and quality of
life.
ESS MOSAS HADS-A
r p r p r p
HADS-D 0.80 0.002* 0.79 0.002* 0.65 0.023*
HADS-A 0.41 NS 0.61 0.035* – –
r: Pearson correlation coefﬁcient, * Statistically signiﬁcant at p 6
0.05, HADS-A: Hospital anxiety and depression scale for anxiety,
HADS-D: Hospital and depression scale for depression,
MOSAS :Maugeri obstructive sleep apnea syndrome questionnaire.
Table 6 Linear regression model of factors predictive of HAD
anxiety and depression scores.
b* P R2
Model A 0.022* 0.459
HAD-A MOSAS 0.678 0.022*
Model B 0.001* 0.727
HAD-D ESS 0.853 0.001*
MOSAS 0.779 0.005*
A and B are 2 different linear regression models for the hospital
anxiety and depression subscale for anxiety and depression
respectively. b#: the regression cooefﬁcient MOSAS:Maugeri
obstructive sleep apnea syndrome questionnaire.
* Statistically signiﬁcant at p 6 0.05.
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the respiratory events [10]. Sleep fragmentation is the primary
cause of excessive daytime sleepiness (EDS) in OSA patients,
and is suggested to result in the depressive symptomatology.
This last perspective gains support from our ﬁnding that
EDS as measured by the Epworth sleepiness scale (ESS) was
the main predictor for the HAD depression score in the linear
regression analysis (p= 0.001). Many other studies have re-
ported similar correlation with the EDS [4,5,17]. However,
with respect to hypoxemia despite the fact that the AHI and
the ODI were more in depressed patients, it didn’t reach statis-
tical signiﬁcance, suggesting that the severity of depressivesymptoms maybe more related to excessive daytime sleepiness
than to nocturnal hypoxemia.
However, Engleman et al. noted that the effect of depres-
sion in OSA correlated highly with the severity of hypoxic
events measured with AHI [18]. Moreover, recently, prelimin-
ary imaging data suggests that hypoxemia related to OSA
might also play a role in impacting mood. Cerebral metabolic
impairment resulting from recurrent nocturnal hypoxemia in
OSA had previously been observed in several imaging investiga-
tions on OSA [19–21]; independently, white matter hyperinten-
sities (WMH)have been linked to depressive symptomatology in
176 R. Daabis, H. Gharrafstudies on affective disorders [22–26]. Aloia et al. reported in a
small sample of older patients with OSA more subcortical
WMH in the brain MRI of patients with a severe OSA as com-
pared to those with minimal OSA, and a tendency for a positive
correlation between these subcortical hyperintensities and
depression scores on the Hamilton Depression Scale [27].
The high comorbidity of OSA and depression also suggests that
both disorders may share a common neurobiological risk factor.
On the neurotransmitter level, the serotoninergic system has a cen-
tral role as a neurobiological substrate underlying impairments in
the regulations of mood, sleep-wakefulness cycle, and upper air-
way muscle tone control during sleep. Depression is associated
with a functional decrease of serotoninergic neurotransmission,
and is mostly responsible for the alterations in sleep [28]. The phys-
iopathology of OSA involves numerous factors, among which the
abnormal pharyngeal collapsibility during sleep is one of the most
compelling. Serotonin delivery to upper airway dilatator motor
neurons has been shown to be reduced in dependency of the vigi-
lance state [29]. This leads to reductions in dilator muscle activity
speciﬁcally during sleep, which may contribute to sleep apnea.
However, whereas the role of serotonin in mood disorders has
been largely documented, its involvement in the pathophysiology
of sleep apnea remains to be clariﬁed [10].
Moreover, OSA and depression share other common risk
factors, as both have independently been shown to be associ-
ated with metabolic syndrome, and also with the development
of cardiovascular disease [30,31].
Several previous investigations examining the covariation
between depression score of patients with SDB and nocturnal
variables (AHI and nocturnal hypoxemia) found little [8,32] or
no evidence of a linear relation [33,34], suggesting that the pres-
ence of OSA and its severity is not the primary cause of psycho-
pathological changes in SDB patients. Similarly, in a regression
analysis of variables associated with sleep apnea, we found no
association between AHI or other sleep parameters and HAD
anxiety or depression score. Nevertheless, a strong relationship
was found between HAD depression score and sleepiness, using
the ESS. This ﬁnding further supports the suggestion of a possi-
ble shared pathway between these conditions. As several studies
found that obstructive sleep apnea is associated with elevated
levels of the cytokines IL6 and tumor necrosis factor [35,36].
These cytokines have been proposed as themediators of daytime
sleepiness in this condition. Major depression has also been
shown to be associated with an immune response involving pro-
inﬂammatory cytokines; IL 1, IL 6 and interferon [37].
Reports of anxiety in the context of OSAS are less common
than depression but are nevertheless not unusual. Moreover,
many research literatures concerned themselves mainly with
whether or not there are clinical levels of depression. Thus,
the full complex array of psychopathology may not have been
adequately acknowledged in quantity and quality [38]. Since
we have demonstrated a high prevalence of anxiety in addition
to depression in the patients’ group, in addition to the positive
correlation found between the two psychiatric comorbidities in
these patients (p= 0.023), this represents an oversight in the
investigation into the relationship between OSAS and mental
health, as recent evidence suggests that when depression is con-
sidered in conjunction with other symptoms it is more closely
tied to the biological markers of OSAS [39].
Another important ﬁnding is that the QOL, measured by
MOSAS questionnaire, was a strong predictor for both; the
HAD anxiety and depression scores (p= 0.022 and 0.005respectively). Very few published reports have examined the
relationship between the QOL and mood [40]. The ﬁndings that
the QOL may play an important role in anxious or depressive
state is reasonable because this reduced QOL reﬂects deﬁcits
in functioning across a number of areas [41]. Such difﬁculties
may be so severe that job performances and family life may be
affected, leading in turn to emotional disturbances and person-
ality changes. These ﬁndings support the hypothesis that some
of the psychopathological changes described in patients with
OSAS are likely to reﬂect the reduced alertness and the reduced
vigor and QOL related to breathing disorders [5].
Moreover, the reduced QOL present in SDB patients may af-
fect their general health perception and their functional and emo-
tional well-being inducing, in turn, personality changes such as
aggressiveness, irritability, anxiety or depression, all expressing
adaptation of the patients to their worsening life condition [42].
This study has its own limitations; ﬁrst, the unequal num-
ber of males and females, as the gender of subjects may have
a signiﬁcant impact on mood; since women are more vulnera-
ble to mood alterations. Also, it is important to take note of
the limitations of mood scales, which are not proper diagnostic
tools for the detection of depression or anxiety; they only rep-
resent depressive and anxious symptoms, however diagnosis of
the clinical entity requires a psychiatric consultation.
In conclusion, our study demonstrated that anxious and
depressive symptoms are highly prevalent in patients with mod-
erate to severe untreated obstructive sleep apnea. The severity of
depressive symptoms maybe more related to excessive daytime
sleepiness than to nocturnal hypoxemia. The reduced QOL is
a strong predictor of psychiatric symptoms in OSA patients.
Therefore, in clinical practice we think it is feasible to be
alert to psychiatric symptoms in patients with OSAS and rou-
tine screening with instruments like the HAD scale should be
encouraged, to improve QOL and optimize diagnosis and ther-
apy in these patients.
Future research is needed to investigate the causal relation-
ship between psychiatric symptoms and OSAS, as well as the
appropriate treatment for these comorbidities.Declaration of interest
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